As a result of the decision, Shilpa will not be eligible to receive FDA approval for its lenvatinib mesylate generic until February 2036.

EXEL gains 28.2% YTD, driven by Cabometyx growth, pipeline progress and an increase in stock buyback authorizations.

Among the 43 evaluable patients treated with sevabertinib, the confirmed objective response rate was 72.1%.

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes ...

Lung cancer is the malignant tumor with the highest incidence and mortality rate in the world. With the in-depth research of ...

Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

Five early-career Fred Hutch/UW researchers received prestigious Young Investigator Awards from Conquer Cancer, the ASCO Foundation during this year's annual meeting of the American Society of ...